ӳ����ý

Expanded “connectivity map” creates more than 1.3 million gene expression profiles of drug treatment and genetic perturbation, accelerating research on small molecules and gene function.

Improved methods validate the use of blood samples for studying patients’ cancer genomes

Coinciding with the second anniversary of the breakthrough patient-driven research movement, this first of many data releases aims to accelerate progress in metastatic breast cancer research.

The ӳ����ý Cancer Dependency Map team adds CRISPR-based data from 342 cancer cell lines to their growing catalog of genetic dependencies in cancer, and a new method for ensuring that data's accuracy.

A mutation pattern or “signature” linked to defects in two genes points to other ways an important DNA repair mechanism can be shut off in breast cancer.

Cancer cells thrive despite harboring mutations that should kill them. By mapping the dependencies cancer cells rely on for survival, researchers hope to reveal new treatment opportunities.

While mutations in protein-coding genes have held the limelight in cancer genomics, those in the noncoding genome (home to the regulatory elements that control gene activity) may  also have powerful roles in driving tumor growth. A new study reveals recurrent mutations in nine such noncoding elements in breast cancer.